Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors
- 5 November 2022
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 352, 637-651
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Profound Impairment of Adaptive Immune Responses by Alkylating ChemotherapyThe Journal of Immunology, 2013
- CarfilzomibDrugs, 2012
- Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in RatsDrug Metabolism and Disposition, 2011
- Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailabilityEuropean Journal of Pharmaceutical Sciences, 2010
- Understanding the structure and stability of paclitaxel nanocrystalsInternational Journal of Pharmaceutics, 2010
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Differential effects of age on circulating and splenic leukocyte populations in C57BL/6 and BALB/c male miceImmunity & Ageing, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007